IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!

In this episode of #AskDrDurie, Dr. Brian Durie talks about the new diagnostic guidelines and tests that can be used to diagnose myeloma early, before CRAB features have emerged. These criteria have been published in a new publication available on myeloma.org.

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a patient's question about why the recent FDA ODAC hearing rejected the use of new drug panobinostat for myeloma. He also discusses other HDAC inhibitors that are currently in development.

In this week’s special #AskDrDurie episode, Dr. Brian Durie of the IMF takes a look at the December 2014 ASH (American Society of Hematology) meeting in San Francisco. He previews what abstracts will be presented and talks about news to expect out of the meeting.

In this week's episode of #AskDrDurie, Dr. Brian G.M. Durie of the IMF answers a patient's question regarding stem cells. If they are harvested in a specific facility, can they be moved and stored elsewhere later?

In this week’s episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a patient question regarding IgA myeloma and tests used to monitor it, specifically the Hevylite™ test. Watch this video to learn all about Hevylite.

Inspired by last week's #AskDrDurie episode in which Dr. Brian Durie of the IMF explained the definition of remission when it comes to myeloma patients, this new episodes is a follow-up. Here, Dr. Durie explains why a myeloma patient might experience a short remission period, even if high-risk features have not been identified.